An elevated plasma fibrinogen level is increasingly accepted as an independent risk indicator of cardiovascular disease. This has enhanced the interest in identifying agents that can normalize elevated plasma fibrinogen levels. One group of agents with this capacity are the fibric acid derivatives, e.g. ciprofibrate and gemfibrozil.
We studied fibrinogen levels after 12 weeks of treatment with ciprofibrate (n = 48) and gemfibrozil (n = 51) in hypercholesterolemic patients. The correlation of the decrease in fibrinogen with lipid lowering and the contribution of the acute phase and genetic polymorphisms to this decrease were also evaluated.
After 12 weeks of treatment, the fibrinogen levels were significantly decreased (p<0.0005) with both drugs, although the decrease in the ciprofibrate group (mean 3.4 g/1 pre-treatment to 2.4 g/1 after 12 weeks) was larger than in the gemfibrozil group (mean 3.4 g/1 to 3.0 g/1.). The lipid lowering effect was comparable for the two drugs but there was no correlation for either ciprofibrate or gemfibrozil between the lipid lowering and the magnitude or the velocity of the fibrinogen lowering effect. An attenuation of the major regulatory mechanism of plasma fibrinogen levels, the acute phase reaction, was invoked as the underlying mechanism. However, pre-treatment C-reactive protein levels were not increased and did not change after treatment. Moreover, no effects of the polymorphisms of the fibrinogen β-gene on the decrease of the plasma fibrinogen levels were observed. This suggests that a new, as yet unknown, mechanism is involved in fibrinogen lowering by fibrates.
References
1
Meade TW,
Brozovic M,
Haines AP,
Imenson JD,
Mellows S,
Miller GJ,
North MRS,
Stirling Y,
Thompson SG.
Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 02: 533-538
3
Heinrich J,
Balleisen L,
Schulte H,
Assmann G,
van deLooJ.
Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscl Thromb 1994; 14: 54-59
5
Wilhelmsen L,
Svärdsudd K,
Korsan-Bengtsen K,
Larsson B,
Welin L,
Tibblin G.
Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
7
Thompson SG,
Kienast J,
Pyke S,
Haverkate F,
van deLooJ.
for the EC AT Angina Pectoris Study Group. Haemostatic risk factors and the risk for myocardial infarction or sudden cardiac death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641
11
Niort G,
Bulgarelli A,
Cassader M,
Pagano G.
Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113
12
Bo M,
Bonino F,
Neirotti M,
Gottero M,
Pemigotti L,
Molaschi M,
Fabris F.
Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106
13
Branchi A,
Rovellini A,
Sommariva D,
Gugliandolo AG,
Fasoli A.
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-243
14
Aimer LO,
Kjelström T.
The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986; 61: 81-85
15
Caimi G,
francavilla g,
Romano A,
Catania A,
Santonocito G,
Sarno A.
Blood rheology changes during bezafibrate treatment. Br J Clin Practice 1988; 42: 456-458
17
Andersen P,
Smith P,
Seljeflot I,
Brataker S,
Amesen H.
Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174-177
18
O’Brien J,
Etherington MD,
Shuttleworth R,
Adams C,
Middleton JE.
et al
A pilot study of the effect of gemfibrozil on some haematological parameters. Thromb Res 1982; 26: 275-279
19
Avellone G,
Di GarboV,
Crodova R,
Ranelli G,
De SimoneR,
Bimppiani G.
Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Therapeutic Res 1992; 52: 338-348
22
Baumann H,
Onorato V,
Gauldie J,
Jahreis GP.
Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors in monokines in rat hepatoma cells. J Biol Chem 1987; 262: 9756-9768
24
Humphries SE,
Cook M,
Dubowitz M,
Stirling Y,
Meade TW.
Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 01: 1452-1455
25
Thomas A,
Lamlum H,
Humphries S,
Green F.
Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455(HaeIII), C/T-148(HinIII/VAluI),T/G+1689(AvaII), andBclI(β-fibrinogen) andTaqI(α-fibrinogen), and their detection by PCR. Human Mutation 1994; 03: 79-81
27
Thomas AE,
Green FR,
Kelleher CH,
Wilkes HC,
Brennan PJ,
Meade TW,
Humphries SE.
Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-490
28
Green F,
Hamsten A,
Blombäck M,
Humphries S.
The role of β-fibrinogen genotype in determining plasma levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-920
29
de BartACW,
de MaatMPM,
Hennis BC,
Kluft C.
Longitudinal stability of plasma fibrinogen levels in healthy volunteers. In: Fibrinogen: a “new” cardiovascular risk factor.
Ernst E,
Koenig W,
Lowe GDO,
Meade TW.
eds
Vienna: Blackwell-MZV; 1992: 86-90
31
Knipscheer HC,
de ValoisJC,
van denEndeA,
ten CateJW,
Kastelein JJP.
Ciprofibrate versus Gemfibrozil in the treatment of primary hyperlipidemia. Atherosclerosis 1996; 124 Suppl S75-S81
32
de MaatMPM,
Pietersma A,
Kofflard M,
Sluiter W,
Kluft C.
The complex association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-191
33
Cortellaro M,
Boschetti C,
Cofrancesco E,
Zanussi C,
Catalano M,
de GaetanoG,
Gabrielli L,
Lombardi B,
Specchia G,
Tavazzi L,
Tremoli E,
Della VolpeA,
Polli E.
PLAT Study Group The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis 1991; 90: 109-118
35
Wiseman SA,
Jaye PD,
Powell JT,
Humphries SE,
Greenhalgh RM.
Frequency of DNA polymorphisms of the apolipoprotein B and fibrinogen genes in young patients with peripheral arterial disease. In: Applied Cardiovascular Biology 1989.
Zilla P,
Fasol R,
Callow A.
eds
Int Soc Appl Cardiovasc Biol Basel, Karger. 1990. vol 01. pp 118-123
36
Scarabin PY,
Bara L,
Ricard S,
Poirier O,
Cambou JP,
Arveiler D,
Luc G,
Evans AE,
Samama MM,
Cambien F.
Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscl Thrombos 1993; 13: 886-891
37
Koster T,
Rosendaal FR,
Reitsma PH,
Van derVelden PA,
Briët E,
Vandenbroucke JP.
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms – the Leiden thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722
